SAREUM LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  —

  Not reported

• Cash

  +121%

  £1,365,000 → £3,017,000

• Net assets

  -12.9%

  -£18,451,000 → -£20,826,000

• Employees

  0%

  5 → 5

• Operating profit

  -66.3%

  -£1,692,000 → -£2,813,000

• Profit before tax

  -65.1%

  -£1,660,000 → -£2,741,000

• Wages

  +6.6%

  £530,000 → £565,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. SAREUM LIMITED 2003-11-20 → present
2. SARELA LTD 2003-08-12 → 2003-11-20

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Moore Kingston Smith LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”

Significant events

• “In July 2025, Sareum reported positive topline results from the Phase 1 clinical trial conducted in healthy volunteers in Australia.”
• “In October 2025, Sareum discontinued its 16-week GLP preclinical toxicology study for SDC-1801 after unexpected safety findings were observed.”
• “During the period, Sareum successfully acquired the licence for SRA737 following the termination of a licensing agreement between CPF and a US-based licensee in December 2024.”
• “Sareum has recently conducted targeted preclinical studies to evaluate the potential of its TYK2/JAK1 compounds in central nervous system ("CNS") indications.”
• “Post-period, the new TYK2 Neuroscience collaboration extended the relevance of Sareum's science into neuro-inflammatory disease, adding long-term optionality to the portfolio.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.